Ascend Wellness Holdings reported fourth‑quarter 2025 revenue of $120.5 million, a 3.4 % sequential decline, and full‑year revenue of $500.6 million, down 10.9 % YoY. Net loss widened to $48.7 million from $25.8 million in Q3, driven largely by a $17.0 million arbitration settlement and higher G&A costs linked to its densification program.
Adjusted EBITDA margin rose to 25.1 % in Q4 from 24.9 % in Q3, the highest level in the company’s history. The improvement reflects a shift toward higher‑margin finished‑goods sales and disciplined cost management, offsetting the impact of the arbitration expense.
The company missed analyst consensus on both revenue and earnings. Revenue fell $1.85 million, 1.51 % below the $122.35 million estimate, while EPS of –$0.24 was 140 % worse than the –$0.10 consensus.
Investors reacted negatively, citing the EPS miss and revenue miss as key concerns, while noting the margin expansion as a positive operational development.
Cash and cash equivalents stood at $85.7 million as of December 31 2025, and the company has no significant near‑term debt maturities, reinforcing its strong liquidity position.
CEO Samuel Brill emphasized the company’s continued focus on densification, with eight new stores added in Q4, bringing the total to 48. The company remains on track for a 60‑store target by the end of 2026 and continues to prioritize a customer‑focused, CPG operating model.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.